InMode Ltd. (INMD)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 206 | 358 | 454 | 492 | 395 | 370 | 375 | 370 |
| Operating profit | $m | 85 | 69 | ||||||
| Net profit | $m | 75 | 165 | 162 | 198 | 181 | 94 | 78 | 84 |
| EPS reported | $ | 1.43 | 1.23 | ||||||
| Operating cashflow per share | $ | 1.32 | 1.50 | ||||||
| Capex per share | $ | 0.02 | 0.02 | ||||||
| FCF per share | $ | 1.30 | 1.48 | ||||||
| Free cash flow | $m | 84 | 87 | ||||||
| Net debt | $m | -550 | -501 | ||||||
| Book value equity | $m | 683 | 629 | ||||||
| Book value per share | $ | 10.44 | 10.60 | ||||||
| Number of shares | m | 65.44 | 59.38 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 10.27 | 11.59 | ||||||
| P/B LTM | x | 1.39 | 1.51 | ||||||
| P/S LTM | x | 2.56 | 2.53 | ||||||
| P/FCF LTM | x | 11.26 | 10.86 | ||||||
| EV/EBITDA LTM | x | 5.95 | 7.84 | ||||||
| EV/Sales LTM | x | 1.78 | 1.28 | ||||||
| Earnings Yield LTM | % | +9.74% | +8.63% | ||||||
| FCF Yield | % | +8.88% | +9.21% | ||||||
| Quality | |||||||||
| ROE | % | +13.73% | +11.80% | ||||||
| ROIC | % | +10.39% | +9.20% | ||||||
| Operating margin | % | +23.05% | +18.47% | ||||||
| Gross margin | % | +78.54% | +76.52% | ||||||
| FCF/Sales | % | +22.75% | +23.34% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -36.44% | -45.33% | ||||||
| Sales Growth YoY | % | -6.16% | -5.11% | ||||||
| Net Income Growth YoY | % | -48.24% | -57.24% | ||||||
| FCF Growth | % | -36.15% | -33.74% | ||||||
| Operating Profit Growth | % | -24.12% | -38.50% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 6.37 | 19.65 | ||||||
| Net Debt/EBITDA | x | -2.61 | -4.65 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +0.53% | 0.00% | ||||||
| Net debt/Equity | x | -0.81 | -0.80 | ||||||
| Gross debt/equity | x | 0.02 | 0.01 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
InMode Ltd. is a medical technology company that engineers, produces, and commercializes aesthetic medical devices globally, including within the United States. The firm's product portfolio is extensive, covering both less-invasive and non-surgical solutions. A core focus lies in their minimally invasive offerings, which leverage exclusive radiofrequency-assisted lipolysis (RFAL) and deep subdermal fractional radiofrequency technologies. These advanced devices facilitate a range of procedures, such as liposuction with concurrent skin firming, body and facial sculpting, intensive skin resurfacing treatments, and various women's health-related aesthetic interventions. Beyond these, InMode also provides non-invasive medical aesthetic products designed to address numerous cosmetic concerns. These include lasting hair removal, facial skin revitalization, the reduction of wrinkles, cellulite improvement, enhancing overall dermal quality and texture, and treating minor vascular and pigmented skin imperfections. Furthermore, the company develops automated, hands-free medical aesthetic systems for applications like dermal tightening, adipose tissue reduction, and muscular toning. Established in 2008, InMode Ltd. operates from its headquarters in Yokneam, Israel. The company was previously known as Invasix Ltd. before officially changing its name in November 2017.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
InMode Ltd. is a medical technology company that engineers, produces, and commercializes aesthetic medical devices globally, including within the United States. The firm's product portfolio is extensive, covering both less-invasive and non-surgical solutions. A core focus lies in their minimally invasive offerings, which leverage exclusive radiofrequency-assisted lipolysis (RFAL) and deep subdermal fractional radiofrequency technologies. These advanced devices facilitate a range of procedures, such as liposuction with concurrent skin firming, body and facial sculpting, intensive skin resurfacing treatments, and various women's health-related aesthetic interventions. Beyond these, InMode also provides non-invasive medical aesthetic products designed to address numerous cosmetic concerns. These include lasting hair removal, facial skin revitalization, the reduction of wrinkles, cellulite improvement, enhancing overall dermal quality and texture, and treating minor vascular and pigmented skin imperfections. Furthermore, the company develops automated, hands-free medical aesthetic systems for applications like dermal tightening, adipose tissue reduction, and muscular toning. Established in 2008, InMode Ltd. operates from its headquarters in Yokneam, Israel. The company was previously known as Invasix Ltd. before officially changing its name in November 2017.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free